Excision repair cross-complementation group 6 gene polymorphism is associated with the response to folfirinox chemotherapy in asian patients with pancreatic cancer

Young Hoon Choi, Younggyun Lim, Ji Kon Ryu, Woo Hyun Paik, Sang Hyub Lee, Yong Tae Kim, Ju Han Kim

Research output: Contribution to journalArticlepeer-review

Abstract

FOLFIRINOX is currently one of the standard chemotherapy regimens for pancreatic cancer patients, but little is known about the factors that can predict a response to it. We performed a study to discover novel DNA damage repair (DDR) gene variants associated with the response to FOLFIRINOX chemotherapy in patients with pancreatic cancer. We queried a cohort of pancreatic cancer patients who received FOLFIRINOX chemotherapy as the first treatment and who had tissue obtained through an endoscopic ultrasound-guided biopsy that was suitable for DNA sequencing. We explored variants of 148 DDR genes based on whole exome sequencing and performed multivariate Cox regression to find genetic variants associated with progression-free survival (PFS). Overall, 103 patients were included. Among 2384 variants of 141 DDR genes, 612 non-synonymous variants of 123 genes were selected for Cox regression analysis. The multivariate Cox model showed that rs2228528 in ERCC6 was significantly associated with improved PFS (hazard ratio 0.54, p = 0.001). The median PFS was significantly longer in patients with rs2228528 genotype AA vs. genotype GA and GG (23.5 vs. 16.2 and 8.6 months; log-rank p < 0.001). This study suggests that rs2228528 in ERCC6 could be a potential predictor of response to FOLFIRINOX chemotherapy in patients with pancreatic cancer.

Original languageEnglish
Article number1196
Pages (from-to)1-11
Number of pages11
JournalCancers
Volume13
Issue number6
DOIs
StatePublished - 2 Mar 2021

Keywords

  • DNA repair
  • ERCC6
  • FOLFIRINOX
  • Pancreatic cancer
  • Progression-free survival

Fingerprint

Dive into the research topics of 'Excision repair cross-complementation group 6 gene polymorphism is associated with the response to folfirinox chemotherapy in asian patients with pancreatic cancer'. Together they form a unique fingerprint.

Cite this